We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Aytu BioScience Announces Publication of Results from Natesto Spermatogenesis Study in Journal of Urology. *Nasally-Administered Natesto Testosterone Replacement Therapy Increases Serum Testosterone, Improves Hypogonadal Symptoms While Simultaneously Preserving Semen Parameters and Gonadotropin Hormonesnewsfilter.io
AYTU (MC $16 M) (Cash $11.8 M) 4 Marketed Products +Big Drug | Stock Discussion ForumsShare